Structure<unk>  is an analog of the human GIP hormone (with a C20 fatty-diacid portion attached, used to optimise the uptake and metabolism of the compound. The fatty-diacid section (eicosanedioic acid) is linked via a glutamic acid and two (2-(2-aminoethoxy)ethoxy)acetic acid units to the side chain of the lysine residue. This arrangement allows for a much longer half life, extending the time between doses, because of its high affinity to albumin. Synthesis The synthesis of<unk>  was first disclosed in patents filed by Eli Lilly and Company. This uses standard solid phase peptide synthesis, with an allyloxycarbonyl protecting group on the lysine at position 20 of the linear chain of amino acids, allowing a final set of chemical transformations in which the sidechain amine of that lysine is derivatized with the lipid-containing fragment. Large-scale manufacturing processes have been reported.
Tirzepatide
Plecanatide
Oprelvekin
Vosoritide
Lixisenatide
Abaloparatide
Bulevirtide
Eptifibatide